Glenmark Pharmaceuticals on Tuesday said its unit has inked a marketing and distribution agreement with BeiGene to commercialise the latter’s oncology medicines, Tislelizumab and Zanubrutinib in India.
Glenmark Specialty SA, a unit of Mumbai-based drug maker, has inked exclusive marketing and